Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

EAACI food allergy and anaphylaxis guidelines: diagnosis and management of food allergy

Food allergy can have significant effects on morbidity and quality of life and can be costly in terms of medical visits and treatments.

Research

Genome-wide association study identifies peanut allergy-specific loci and evidence of epigenetic mediation in US children

Food allergy (FA) affects 2%-10% of US children and is a growing clinical and public health problem.

Research

Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants

The purpose of this article is to highlight emerging evidence for existing allergy prevention guidelines regarding potential benefits of supporting early...

Research

Food Allergy

Food allergies have become more common in our community, with up to one in ten young children now affected. Reactions can range from mild hives to life threatening anaphylaxis and breathing difficulties. The most common food allergies are to egg, peanut, tree nuts, cow’s milk, fish, shellfish, sesame, wheat and soy.

Research

Pertussis immunisation in infancy and atopic outcomes: A protocol for a population-based cohort study using linked administrative data

The burden of IgE-mediated food allergy in Australian born children is reported to be among the highest globally. This illness shares risk factors and frequently coexists with asthma, one of the most common noncommunicable diseases of childhood.

Research

Gene-vitamin D interactions on food sensitization: A prospective birth cohort study

It has been hypothesized that vitamin D deficiency (VDD) contributes to the development of food sensitization (FS) and then food allergy.

News & Events

Cow’s milk protein allergies on the rise in our kids

Up to three out of every 100 babies develop cow's milk protein allergy (CMPA) in their first year of life – and this number appears to be on the rise

Research

Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE

The pivotal phase 3 EPITOPE trial, a 12-month, double-blind, placebo-controlled study of epicutaneous immunotherapy with the VIASKIN patch containing 250 μg of peanut protein (VP250), previously reported significant treatment response versus placebo in peanut-allergic toddlers aged 1 through 3 years.

Research

Identifying gene network patterns and associated cellular immune responses in children with or without nut allergy

Although evidence suggests that the immune system plays a key role in the pathophysiology of nut allergy, the precise immunological mechanisms of nut allergy have not been systematically investigated. The aim of the present study was to identify gene network patterns and associated cellular immune responses in children with or without nut allergy.

Research

Epigenetic modifications: Mechanisms of disease and biomarkers of food allergy

The rise in IgE-mediated food allergy in recent times is the likely result of gene-environment interactions mediated via epigenetic pathways.